Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Equillium Inc (EQ)

Equillium Inc (EQ)
0.4000 x 20 0.5200 x 20
Post-market by (Cboe BZX)
0.4552 -0.0173 (-3.66%) 04/21/25 [NASDAQ]
0.4000 x 20 0.5200 x 20
Post-market 0.4552 unch (unch) 15:47 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.4252
Day High
0.4725
Open 0.4466
Previous Close 0.4725 0.4725
Volume 44,800 44,800
Avg Vol 173,030 173,030
Stochastic %K 51.06% 51.06%
Weighted Alpha -46.44 -46.44
5-Day Change -0.0238 (-4.97%) -0.0238 (-4.97%)
52-Week Range 0.3642 - 1.8900 0.3642 - 1.8900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,877
  • Shares Outstanding, K 35,719
  • Annual Sales, $ 41,100 K
  • Annual Income, $ -8,070 K
  • EBIT $ -8 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.87
  • Price/Sales 0.38
  • Price/Cash Flow N/A
  • Price/Book 0.81
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $-0.16 on 03/27/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 411.74% ( -123.15%)
  • Historical Volatility 163.88%
  • IV Percentile 61%
  • IV Rank 41.09%
  • IV High 928.12% on 07/23/24
  • IV Low 51.51% on 05/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 182
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 255
  • Open Int (30-Day) 639

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.26
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -175.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3642 +24.99%
on 03/31/25
Period Open: 0.7730
0.8300 -45.16%
on 03/25/25
-0.3178 (-41.11%)
since 03/21/25
3-Month
0.3642 +24.99%
on 03/31/25
Period Open: 0.6401
1.0300 -55.81%
on 02/06/25
-0.1849 (-28.89%)
since 01/21/25
52-Week
0.3642 +24.99%
on 03/31/25
Period Open: 1.6100
1.8900 -75.92%
on 05/10/24
-1.1548 (-71.73%)
since 04/19/24

Most Recent Stories

More News
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.4552 (-3.66%)
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 0.4552 (-3.66%)
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.4552 (-3.66%)
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation...

EQ : 0.4552 (-3.66%)
Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 0.4552 (-3.66%)
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was...

EQ : 0.4552 (-3.66%)
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

EQ : 0.4552 (-3.66%)
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited,...

EQ : 0.4552 (-3.66%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, EQ, MTCR, SESN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MTCR : 0.5814 (-1.29%)
MVBF : 15.88 (+0.25%)
SESN : 0.6288 (+7.29%)
EQ : 0.4552 (-3.66%)
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

MTCR : 0.5814 (-1.29%)
OPNT : 20.65 (-0.58%)
EQ : 0.4552 (-3.66%)
IMGO : 36.01 (+0.03%)

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 0.5240
2nd Resistance Point 0.4983
1st Resistance Point 0.4767
Last Price 0.4552
1st Support Level 0.4294
2nd Support Level 0.4037
3rd Support Level 0.3821

See More

52-Week High 1.8900
Fibonacci 61.8% 1.3071
Fibonacci 50% 1.1271
Fibonacci 38.2% 0.9471
Last Price 0.4552
52-Week Low 0.3642

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.